Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Apo-lipoproteins, lipids and risk of cancer.

Author

  • Signe Borgquist
  • Talha Butt
  • Peter Almgren
  • Dov Shiffman
  • Tanja Stocks
  • Marju Orho-Melander
  • Jonas Manjer
  • Olle Melander

Summary, in English

The epidemiological evidence for an obesity-cancer association is solid, whereas the association between obesity-associated lipoprotein levels and cancer is less evident. We investigated circulating levels of Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB), LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) and association to risk of overall cancer and common cancer forms. The Malmö Diet and Cancer Study, a population-based prospective cohort study, enrolled 17,035 women and 11,063 men (1991-1996). Incident cancer cases were ascertained by record linkage with the Swedish Cancer Registry until end of follow-up, Jan 1(st) 2012. Baseline serum levels of ApoA1 and ApoB were analyzed for the entire cohort, and HDL-C and LDL-C levels in 5,281 participants. Hazard ratios, with 95% confidence interval, were calculated using Cox's proportional hazards analysis. In the entire cohort, none of the exposures were related to overall cancer risk (HRadj ApoA1=0.98, 95%CI: 0.95,1.01; HRadj ApoB=1.01, 95%CI: 0.98-1.04). Among men, ApoB was positively associated with cancer risk (HRadj ApoB=1.06, 95%CI: 1.01,1.10). Female breast cancer risk was inversely associated with ApoB (HRadj =0.92, 95%CI: 0.86,0.99). Among both genders, ApoA1 was inversely associated with lung cancer risk (HRadj =0.88, 95%CI: 0.80,0.97), whereas high ApoB increased lung cancer risk (HRadj =1.08, 95%CI: 0.99,1.18). Colorectal cancer risk was increased with high ApoB (HRadj =1.08, 95%CI: 1.01,1.16) among both genders. Apolipoprotein levels were not associated with prostate cancer incidence. Circulating levels of apolipoproteins are associated with overall cancer risk in men and across both genders with breast, lung, and colorectal cancer risk. Validation of these findings may facilitate future primary prevention strategies for cancer. This article is protected by copyright. All rights reserved.

Department/s

  • Breast cancer prevention & intervention
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Breastcancer-genetics
  • Diabetes - Cardiovascular Disease
  • Surgery
  • Department of Clinical Sciences, Malmö
  • EpiHealth: Epidemiology for Health

Publishing year

2016-01-25

Language

English

Pages

2648-2656

Publication/Series

International Journal of Cancer

Volume

138

Issue

11

Document type

Journal article

Publisher

John Wiley and Sons

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Breast cancer prevention & intervention
  • Diabetes - Cardiovascular Disease
  • Surgery

ISBN/ISSN/Other

  • ISSN: 0020-7136